drugset / Trial / NCT07654283

Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions

NCT07654283

Phase 2 Not yet recruiting 70 enrolled AusperBio Therapeutics Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with CHB treated with Nucleos(t)ide Analogue (NAs).

Timeline

Start
2026-06-17
Primary completion
2027-03-24
Completion
2028-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject AHB-137 Antisense oligonucleotide Subcutaneous